| language |
eng
|
| Author |
Ono, Takaaki
Divison of Hematology, Hamamatsu University School of Medicine, Shizuoka, Japan
Takahashi, Naoto
Department of Hematology, Nephrology, and Rheumatology, Akita University School of Medicine, Akita, Japan
Kizaki, Masahiro
Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Kawaguchi, Tatsuya
Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan
Yamamoto , Kazuhito
Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan
Ohnishi, Kazunori
Tokai‐Hokuriku Block Blood Center, Seto, Japan
Naoe, Tomoki
National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
Matsumura, Itaru
Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka‐Sayama, Japan
|
| Subject | chronic myeloid leukemia
comorbidity
dasatinib
imatinib
nilotinib
|
| Journal Title |
CANCER SCIENCE
|
| ISSN | 1347-9032
|
| ISSN（Online） | 1349-7006
|
| Published Date | 2020-07-22
|
| DOI | |
| Publisher | WILEY
|
| NII Type |
Journal Article
|
| OAI-PMH Set |
Faculty of Medicine
|
| Remark | This sub-analysis was performed based on previously published data from the New TARGET observational study 1 (UMIN 00003581) conducted by the JSH. The New TARGET observational study 1 was supported by research funding to JSH from Novartis Pharmaceuticals and Bristol-Myers Squibb. We would like to express our gratitude to all the study participants and their families, and the study investigators at participating study sites. We also thank the New TARGET data center (EPS. Co.).
|
